Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-02-06
DOI
https://doi.org/10.3389/fphar.2026.1644757
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis

Zijing Zhou, Meng Wang, Zhihong Zuo, Ting Wu
Frontiers in Pharmacology
Diabetes Treatment and Management
article

Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis

Zijing Zhou, Meng Wang, Zhihong Zuo, Ting Wu
article en

Abstract

No abstract available for this paper.
Frontiers in PharmacologyVol. 17
Central South University (CN), Sichuan University (CN), National Clinical Research (US), Xiangya Hospital Central South University (CN)
National Natural Science Foundation of China, China Postdoctoral Science Foundation, Xiangya Hospital, Central South University
Good health and well-being
Openalex Percentile: Top 68%
Diabetes Treatment and Management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.